The Chinese Center for Drug Evaluation (CDE) of the National Medical Products Administration has accepted for review Beigene’s application seeking approval for tislelizumab, in combination with standard chemotherapy, as a first-line treatment for people with advanced non-squamous non-small cell lung cancer (NSCLC). This is Beigene’s second supplemental new drug application (sNDA) in China for its experimental candidate tislelizumab. The first, accepted for review in April, asked that this first-line combination therapy be approved for people with advanced squamous NSCLC.…
You must be logged in to read/download the full post.
The post First-line Tislelizumab Plus Chemo Under Review in China for Advanced NSCLC appeared first on BioNewsFeeds.